

Instructions for Authors 2015

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear inline in the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear inline in the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references.

Manuscripts must be submitted only through our online submission system at: <http://www.iiar-submissions.com/login.html>

In case a submission is incomplete, the corresponding Author will be notified accordingly.

Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles published in 2015 are entitled to a complimentary online subscription to Anticancer Research 2015. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Copyright© 2015 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees. (For further information please click [here](#))
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions to authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to AR.
 - plagiarism is detected by plagiarism screening services.

(Rejection rate (2014): 65%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.

(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Salvage Treatment with Intracerebrospinal Fluid Thiotepa in Patients with Leptomeningeal Metastasis After Failure of Methotrexate-based Treatment. K.-M. CHO, Y.J. KIM, S.H. KIM, J.W. KIM, J.-O. LEE, J.H. HAN, K.-W. LEE, J.H. KIM, C.-Y. KIM, S.-M. BANG, I.-A. KIM, J.S. KIM, J.-S. LEE (<i>Seongnam; Seoul, Republic of Korea</i>)	5631
Preoperative Lower Body Mass Index Correlates with Poorer Prognosis in Patients Undergoing Curative Laparoscopic Surgery for Colorectal Cancer. R. URATANI, Y. TOIYAMA, T. SHIMURA, K. MORI, H. FUJIKAWA, J. HIRO, M. OHI, Y. INOUE, K. TANAKA, T. ARAKI, Y. MOHRI, M. KUSUNOKI (<i>Mie, Japan</i>)	5639
Hematogenous Splenic Metastases as an Independent Negative Prognosis Factor at the Moment of Primary Cytoreduction in Advanced Stage Epithelial Ovarian Cancer – A Single Center Experience. N. BACALBASA, I. BALESU, S. DIMA, V. BRASOVEANU, I. POPESCU (<i>Bucharest, Romania</i>)	5649
Diagnostic Accuracy of Tumor Markers CYFRA21-1 and CA125 in the Differential Diagnosis of Ascites. J. TRAPÉ, G. GURT, J. FRANQUESA, J. MONTESINOS, A. ARNAU, M. SALA, F. SANT, E. CASADO, J.M. ORDEIG, C. BERGOS, F. VIDA, P. SORT, Á. ISAVA, M. GONZÁLEZ, R. MOLINA (<i>Manresa; Vic; Barcelona, Spain</i>)	5655
Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma. I. TRÁVNÍČEK, J. BRANŽOVSKÝ, K. KALUSOVÁ, O. HES, L. HOLUBEC, K.B. PELE, T. ÜRGE, M. HORA (<i>Pilsen, Czech Republic</i>)	5661
Drug-resistance Profile in Multiple-relapsed Childhood Acute Lymphoblastic Leukemia. M. POGORZALA, M. KUBICKA, B. RAFINSK, M. WYSOCKI, J. STYCZYNSKI (<i>Bydgoszcz, Poland</i>)	5667
Relative Uptake Factor of Invasive Ductal Breast Cancer in Breast-specific Gamma Imaging as a Surrogate Parameter for Sub-typing. T. MEISSNITZER, M.W. MEISSNITZER, A. SEYMER, K. HERGAN, D. NEUREITER (<i>Salzburg, Austria</i>)	5671
Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy. M. THALGOTT, B. RACK, T. HORN, M.M. HECK, M. EIBER, H. KÜBLER, M. RETZ, J.E. GSCHWEND, U. ANDERGASSEN, R. NAWROTH (<i>Munich, Germany</i>)	5679
Nutritional Supplement Based on Zinc, Prebiotics, Probiotics and Vitamins to Prevent Radiation-related Gastrointestinal Disorders. D. SCARTONI, I. DESIDERI, I. GIACOMELLI, V. DI CATALDO, L. DI BRINA, A. MANCUSO, I. FURFARO, P. BONOMO, G. SIMONTACCHI, L. LIVI (<i>Florence, Italy</i>)	5687
Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up. L. AGOLLI, M. VALERIANI, S. BRACCI, L. NICOSIA, V. DE SANCTIS, R.M. ENRICI, M.F. OSTI (<i>Rome, Italy</i>)	5693
Defining the Optimal Dose of Stereotactic Radiosurgery for Treating Cerebral Metastases in Elderly Patients. D. RADES, M. DAHLKE, L. DZIGGEL, S. JANSSEN, A. BAJROVIC, N.T. TRANG, M.T. KHOA, S.E. SCHILD (<i>Lübeck; Hannover; Hamburg, Germany; Hanoi, Vietnam; Scottsdale, AZ, USA</i>)	5701
Errata	5705
Book Reviews	5707

Decreased Expression of PDHE1 α Predicts Worse Clinical Outcome in Esophageal Squamous Cell Carcinoma. Y. ZHONG, R. HUANG, X. LI, R. XU, F. ZHOU, J. WANG, H. FAN, M. GOSCINSKI, M. ZHANG, J.-G. WEN, J. M. NESLAND, Z. SUO (<i>Zhengzhou; Anyang, PR China; Oslo, Norway</i>)	5533
Partial Cystectomy with Distal Ureteral Resection and Re-implantation for Locally Invasive Cervical Cancer. N. BACALBASA, I. BALESCU, D. TOMESCU (<i>Bucharest, Romania</i>)	5539
Use of Inflated Foley Catheters to Prevent Early Empty Pelvis Complications Following Pelvic Exenteration. N. BACALBASA, D. TOMESCU, I. BALESCU (<i>Bucharest, Romania</i>)	5543
Endometrial Carcinoma Associated with Ovarian Granulosa Cell Tumors – A Case Report. N. BACALBASA, C. STOICA, I. POPA, G. MIREA, I. BALESCU (<i>Bucharest, Romania</i>)	5547
Sunitinib Malate plus Lomustine for Patients with Temozolomide refractory Recurrent Anaplastic or Low-grade Glioma. J. DUERINCK, S. DU FOUR, W. SANDER, A.-M. VAN BINST, H. EVERAERT, A. MICHOTTE, P. HAU, B. NEYNS (<i>Brussels, Belgium; Regensburg, Germany</i>)	5551
Carbon-ion Radiotherapy for Prostate Cancer: Analysis of Morbidities and Change in Health-related Quality of Life. H. ISHIKAWA, H. KATOH, T. KAMINUMA, H. KAWAMURA, K. ITO, H. MATSUI, J. HIRATO, N. SHIMIZU, Y. TAKEZAWA, H. TSUJI, K. SUZUKI, T. OHNO, T. NAKANO (<i>Ibaraki; Gunma; Chiba, Japan</i>)	5559
Survival and Toxicity Following Chemoradiation for Carcinoma of the Cervix – Impact of Multiple-phase Treatment and Shielding. S. YAHYA, L. BHATT, M. KING, S. PIRRIE, R. WYATT, M.S. ANWAR, A. EL-MODIR, I. FERNANDO (<i>Birmingham; Manchester; Wolverhampton, UK</i>)	5567
Prevalence and Prognostic Value of Lymph Node Dissection in Treating Adrenocortical Carcinoma: A National Experience. S. ALANEE, D. DYNDA, B. HOLLAND (<i>Springfield, IL, USA</i>)	5575
Stereotactic Radiotherapy in the Treatment of Lung Metastases from Bone and Soft-tissue Sarcomas. R. FRAKULLI, F. SALVI, D. BALESTRINI, A. PARISI, M. PALOMBARINI, S. CAMMELLI, M. ROCCA, M. SALONE, A. LONGHI, S. FERRARI, A.G. MORGANTI, G. FREZZA (<i>Bologna, Italy</i>)	5581
Stratified Survival Analysis After Adjuvant Chemotherapy of Colon Cancer Reveals a Benefit for Older Patients. B. MAYER, S. SANDER, S. PASCHKE, D. HENNE-BRUNS, K.-H. LINK, M. KORNMMANN (<i>Ulm; Wiesbaden, Germany</i>)	5587
Lymphatic Vascularization in Prostate Adenocarcinoma: Correlation with Tumor Grade, Androgen Withdrawal and Prognosis. M.R. AMBROSIO, B.J. ROCCA, A. BARONE, A. GINORI, F. CRIVELLI, L. PIRTOLI, M.T. DEL VECCHIO (<i>Siena; Saronno, Italy</i>)	5595
Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer. M.J. BOERS-SONDEREN, I.M.E. DESAR, J.J. FÜTTERER, S.F. MULDER, L.-F. DE GEUS-OEI, P.F. MULDER, W.T.A. VAN DER GRAAF, W.J.G. OYEN, C.M.L. VAN HERPEN (<i>Nijmegen, the Netherlands</i>)	5601
Clinical Outcomes in Early-stage NSCLC Treated with Stereotactic Body Radiotherapy Versus Surgical Resection. E.A. KASTELIJN, S.Y. EL SHAROUNI, F.N. HOFMAN, B.P. VAN PUTTE, E.M. MONNINKHOF, M. VAN VULPEN, F.M.N.H. SCHRAMEL (<i>Nieuwegein; Utrecht, the Netherlands</i>)	5607
What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer? R. S. DAVIES, C. SMITH, M.R. BUTTON, J. TANGUAY, J. BARBER, N. PALANIAPPAN, J. STAFFURTH, J.F. LESTER (<i>Cardiff, Wales, UK</i>)	5615
Comparing Endurance and Resistance Training with Standard Care during Chemotherapy for Patients with Primary Breast Cancer. T. SCHMIDT, B. WEISSER, J. DÜRKOP, W. JONAT, M. VAN MACKELENBERGH, C. RÖCKEN, C. MUNDHENKE (<i>Kiel, Germany</i>)	5623

Signatures of Adverse Pathological Features, Androgen Insensitivity and Metastatic Potential in Prostate Cancer. Y. TOLKACH, A. MERSEBURGER, T. HERRMANN, M. KUCZYK, J. SERTH, F. IMKAMP (Hannover, Germany)	5443
17-Allylamino-17-demethoxygeldanamycin and Herbimycin A Induce Cell Death by Modulating β -Catenin and PI3K/AKT Signaling in FRO Anaplastic Thyroid Carcinoma Cells. S.H. KIM, J.G. KANG, C.S. KIM, S.-H. IHM, M.G. CHOI, H.J. YOO, S.J. LEE (Chuncheon, Republic of Korea)	5453
<i>Clinical Studies</i>	
Impaired Immune Function in Patients Undergoing Surgery for Bone Cancer. J.F. VELÁSQUEZ, M.F. RAMÍREZ, D. AI, V. LEWIS, J.P. CATA (Houston; Temple, TX; Boston, MA, USA)	5461
PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine. C. WEBRE, N. SHONKA, L. SMITH, D. LIU, J. DE GROOT (Bryan; Houston, TX; Omaha, NE, USA)	5467
Higher Red Blood Cell Distribution Width Is an Adverse Prognostic Factor in Chronic-phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. N. IRIYAMA, Y. HATTA, S. KOBAYASHI, Y. UCHINO, K. MIURA, D. KURITA, H. KODAIRA, H. TAKAHASHI, Y. IIZUKA, M. INOUE, M. TAKEI (Tokyo, Japan)	5473
Prognostic Impact of Residual Disease After Neoadjuvant Chemotherapy in 648 Patients with Triple-negative Breast Cancer. P. KERN, G. VON MINCKWITZ, C. PUETTER, S. PAVLIDOU, A. FLACH, R. KIMMIG, M. REZAI (Essen; Neu-Isenburg; Düsseldorf, Germany)	5479
Preoperative Chemotherapy Can Change the Surgical Procedure for Hepatectomy in Patients with Liver Metastasis of Colorectal Cancer. Y. SASAKI, S. OSADA, S. MATSUI, H. IMAI, T. TANAHASHI, Y. TANAKA, N. MATSUHASHI, N. OKUMURA, K. YAMAGUCHI, K. YOSHIDA (Gifu, Japan)	5485
Effect of Increased Radiotoxicity on Survival of Patients with Non-Small Cell Lung Cancer Treated with Curatively Intended Radiotherapy. G. HOLGERSSON, S. BERGSTRÖM, P. LIV, J. NILSSON, P. EDLUND, C. BLOMBERG, J. NYMAN, S. FRIESLAND, S. EKMAN, T. ASKLUND, R. HENRIKSSON, M. BERGQVIST (Gävle; Gothenburg; Stockholm; Uppsala; Umeå, Sweden)	5491
Survival After Distant Metastasis in Head and Neck Cancer. S. WIEGAND, A. ZIMMERMANN, T. WILHELM, J.A. WERNER (Marburg, Germany)	5499
Impact of Pelvic and Para-aortic Lymphadenectomy in Advanced Ovarian Cancer After Neoadjuvant Chemotherapy. L. SCHWARTZ, S. SCHROT-SANYAN, C. BRIGAND, J.-J. BALDAUF, A. WATTIEZ, C. AKLADIOS (Strasbourg, France)	5503
Early and Severe Radiation Toxicity Associated with Concurrent Sunitinib in an Organ Transplant Recipient with Head and Neck Cutaneous Squamous Cell Carcinoma: A Case Report. B.V. MANYAM, T.I. NWIZU, M.L. RAHE, B.A. HARR, S.A. KOYFMAN (Cleveland, OH, USA)	5511
A New Predictive Tool for Optimization of the Treatment of Brain Metastases from Colorectal Cancer After Stereotactic Radiosurgery. D. RADES, M. DAHLKE, N. GEBAUER, T. BARTSCHT, D. HORNUNG, N.T. TRANG, P.C. PHUONG, M.T. KHOA, J. GLIEMROTH (Lübeck; Hamburg, Germany; Hanoi, Vietnam)	5515
The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients. V. BARAK, A. MEIROVITZ, V. LEIBOVICI, J. RACHMUT, T. PERETZ, R. ELIASHAR, M. GROSS (Jerusalem, Israel)	5519
Effects of Pre-surgical Vitamin D Supplementation and Ketogenic Diet in a Patient with Recurrent Breast Cancer. J.J.V. BRANCA, S. PACINI, M. RUGGIERO (Florence, Italy)	5525

Lectin Histochemistry Shows WGA, PHA-L and HPA Binding Increases During Progression of Human Colorectal Cancer. P. HÄGERBÄUMER, M. VIETH, M. ANDERS, U. SCHUMACHER (<i>Hamburg; Bayreuth, Germany</i>)	5333
Quantitative Structure–Cytotoxicity Relationship of Oleoylamides. H. SAKAGAMI, Y. UESAWA, M. ISHIHARA, H. KAGAYA, T. KANAMOTO, S. TERAKUBO, H. NAKASHIMA, K. TAKAO, Y. SUGITA (<i>Sakado; Kiyose; Kanagawa, Japan</i>)	5341
Survivin Down-regulation by α -Santalol Is Not Mediated Through PI3K–AKT Pathway in Human Breast Cancer Cells. A. BOMMAREDDY, K. CRISAMORE, S. FILLMAN, S. BROZENA, J. STEIGERWALT, T. LANDIS, A.L. VANWERT, C. DWIVEDI (<i>Wilkes-Barre, PA; Brookings, SD, USA</i>)	5353
CHM-1 Suppresses Formation of Cell Surface-associated GRP78–p85 α Complexes, Inhibiting PI3K–AKT Signaling and Inducing Apoptosis of Human Nasopharyngeal Carcinoma Cells. M.-L. LIN, S.-S. CHEN, S.-H. NG (<i>Taichung, Taiwan, ROC</i>)	5359
Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer. T. TAMURA, M. OHIRA, H. TANAKA, K. MUGURUMA, T. TOYOKAWA, N. KUBO, K. SAKURAI, R. AMANO, K. KIMURA, M. SHIBUTANI, K. MAEDA, K. HIRAKAWA (<i>Osaka, Japan</i>)	5369
Long Noncoding RNA <i>ANRIL</i> Regulates Proliferation of Non-Small Cell Lung Cancer and Cervical Cancer Cells. M. NAEMURA, C. MURASAKI, Y. INOUE, H. OKAMOTO, Y. KOTAKE (<i>Fukuoka, Japan</i>)	5377
Human Mesenchymal Stem Cells Protect Dorsal Root Ganglia from the Neurotoxic Effect of Cisplatin. A. SCUTERI, M. RAVASI, M. MONFRINI, A. MILANO, G. D’AMICO, M. MILOSO, G. TREDICI (<i>Monza; Milan, Italy</i>)	5383
Individual and Combined Effects of CTLA4-CD28 Variants and Oxidant-Antioxidant Status on the Development of Colorectal Cancer. O. KUCUKHUSEYIN, S. TURAN, K. YANAR, S. ARIKAN, Y. DUZKOYLU, S. AYDIN, U. CAKATAY, B. MEZANI, A.A. FAROOQI, G.A. ISITMANGIL, B. KIRAN, C. CACINA, E.N. YENILMEZ, A. ERGEN, U. ZEYBEK, I. YAYLIM (<i>Istanbul; Kastamonu, Turkey; Lahore, Pakistan</i>)	5391
Sensitivity of Human Malignant Melanoma Cell Lines to Newcastle Disease Virus. M. PAP, J. BÁTOR, J. SZEBERÉNYI (<i>Pécs, Hungary</i>)	5401
Synthetic Bichalcone TSWU-BR23 Induces Apoptosis of Human Colon Cancer HT-29 Cells by p53-Mediated Mitochondrial Oligomerization of BAX/BAK and Lipid Raft Localization of CD95/FADD. M.-L. LIN, S.-S. CHEN, T.-S. WU (<i>Taichung; Tainan, Taiwan, ROC</i>)	5407
Tumor Necrosis Factor- α Genotypes Are Associated with Hepatocellular Carcinoma Risk in Taiwanese Males, Smokers and Alcohol Drinkers. M.-D. YANG, C.-M. HSU, W.-S. CHANG, T.-C. YUEH, Y.-L. LAI, C.-L. CHUANG, S.-C. WANG, L.-B. JENG, H.-X. JI, C.-L. HSIAO, C.-N. WU, C.-W. TSAI, J.-G. CHUNG, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	5417
Preliminary Study: Prominent miRNAs of Breast Malignant Tissues Compared to Normal Tissues in Turkish Patients with Breast Cancer. T. OZTURK, O. KUCUKHUSEYIN, A.P. ERONAT, M.B. TUZUNER, A. DAGLAR-ADAY, N. SAYGILI, H.I. KISAKESEN, F. SEYHAN, M. VELIDEDEOĞLU, Z. CALAY, Ş. İLVAN, H. YILMAZ-AYDOĞAN, O. OZTURK, T. İSBİR (<i>Istanbul, Turkey</i>)	5425
Non-covalent Nanocomplexes of Folic Acid and Reducible Polyethylenimine for Survivin siRNA Delivery. B. ZHENG, S. YANG, M. WANG, X. YANG, L. TENG, J. XIE, L. TENG, R.J. LEE (<i>Changchun, PR China; Columbus, OH, USA</i>)	5433

Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives. D.M. FERGUSON, B.A. JACOBSON, J. JAY-DIXON, M.R. PATEL, R.A. KRATZKE, A. RAZA (<i>Minneapolis, MN, USA</i>)	5211
Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates <i>SOCS3</i> . A. LIVUN, K.J. NEWBERRY, T. MANSOURI, R. KUSEC, S. VERSTOVSEK (<i>Zagreb, Croatia; Houston, TX, USA</i>)	5219
Imaging the Different Mechanisms of Prostate Cancer Cell-killing by Tumor-targeting <i>Salmonella typhimurium</i> A1-R. A. UCHUGONOVA, Y. ZHANG, R. SALZ, F. LIU, A. SUETSUGU, L. ZHANG, K. KOENIG, R.M. HOFFMAN, M. ZHAO (<i>San Diego, CA, USA; Saarbruecken, Germany</i>)	5225
Hyaluronic Acid Inhibitor 4-Methylumbelliferone Activates the Intrinsic Apoptosis Pathway in K562 Chronic Myelogenous Leukemia Cells. H. BAN, O. UCHAKINA, R.J. MCKALLIP (<i>Macon, GA, USA</i>)	5231
Reversal of c-MET-mediated Resistance to Cytotoxic Anticancer Drugs by a Novel c-MET Inhibitor TAS-115. E. KUNII, H. OZASA, T. OGURI, K. MAENO, S. FUKUDA, T. UEMURA, O. TAKAKUWA, H. OHKUBO, M. TAKEMURA, A. NIIMI (<i>Nagoya; Kyoto, Japan</i>)	5241
The <i>In Vitro</i> and <i>In Vivo</i> Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression. C. STENGEL, S.P. NEWMAN, M.P. LEESE, M.P. THOMAS, B.V.L. POTTER, M.J. REED, A. PUROHIT, P.A. FOSTER (<i>London; Oxford; Bath; Birmingham, UK</i>)	5249
Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells. J. LIZALEK, T. MCKENNA, K. HUEGEL, S. MARSH, A. CAROLAN, A. KOBLISKA, E. HEYING, N. GARDNER, G. MILLER, A. KOTECKI, M. HENNINGSEN, A. LUNDT, J. FARLEY, S.M. ELLERBROEK (<i>Waverly, IA, USA</i>)	5263
The New Semisynthetic Cardenolide Analog 3 β -[2-(1-Amantadine)-1-on-ethylamine]-digitoxigenin (AMANTADIG) Efficiently Suppresses Cell Growth in Human Leukemia and Urological Tumor Cell Lines. E. NOLTE, A. SOBEL, S. WACH, H. HERTLEIN, N. EBERT, F. MÜLLER-URI, R. SLANY, H. TAUBERT, B. WULLICH, W. KREIS (<i>Erlangen, Germany</i>)	5271
Gelsolin Is Associated with Longer Metastasis-free Survival and Reduced Cell Migration in Estrogen Receptor-positive Breast Cancer. A.-M. STOCK, F. KLEE, K. EDLUND, M. GRINBERG, S. HAMMAD, R. MARCHAN, C. CADENAS, B. NIGGEMANN, K.S. ZÄNKER, J. RAHNENFÜHRER, M. SCHMIDT, J. G. HENGSTLER, F. ENTSCHLADEN (<i>Witten; Dortmund; Mainz, Germany; Qena, Egypt</i>)	5277
Glucan Supplementation Has Strong Anti-melanoma Effects: Role of NK Cells. V. VETVICKA, J. VETVICKOVA (<i>Louisville, KY, USA</i>)	5287
The Effects of Curcumin-based Compounds on Proliferation and Cell Death in Cervical Cancer Cells. X. ZHANG, R. WANG, G. CHEN, L. DEJEAN, Q.-H. CHEN (<i>Fresno, CA, USA</i>)	5293
Quantitative Structure–Cytotoxicity Relationship of 3-Styryl-2 <i>H</i> -chromenes. Y. UESAWA, H. SAKAGAMI, M. ISHIHARA, H. KAGAYA, T. KANAMOTO, S. TERAKUBO, H. NAKASHIMA, H. YAHAGI, K. TAKAO, Y. SUGITA (<i>Kiyose; Sakado; Kanagawa, Japan</i>)	5299
Zinc Induces Apoptosis of Human Melanoma Cells, Increasing Reactive Oxygen Species, p53 and FAS Ligand. M. PROVINCIALI, E. PIERPAOLI, B. BARTOZZI, G. BERNARDINI (<i>Ancona, Italy</i>)	5309
GADD34 Facilitates Cell Death Resulting from Proteasome Inhibition. L. LIU, S. ITO, N. NISHIO, Y. SUN, N. CHEN, Y. TANAKA, K.-I. ISOBE (<i>Nagoya, Japan</i>)	5317
Tryptase-positive and CD117 Positive Mast Cells Correlate with Survival in Patients with Liver Metastasis. S.E. GIUȘCĂ, I.D. CĂRUNTU, A.M. CÎMPEAN, R.E. AVADANEI, A.R. BALICA, A.A. JITARIU, M. RAICA (<i>Iași; Timișoara, Romania</i>)	5325